MDT - Edwards Life Sciences: 15.76% FCF Margin But With 6.67% Downside Risk And 30% Overvaluation - Time To Prove It
Edwards Life Sciences (NYSE:EW) has shown resilience amidst the recent market uncertainty, with a surprisingly sturdy Q2 exit showcased on July 23rd 2020 with clear guidance moving into the end of FY2020 and 2021. Whilst also beating Revenue and EPS estimates by $133.29 million and $0.10, respectively, the company ultimately registered earnings of $0.34 per share over this period. Current shareholders can take solace in the fact that the company's hero product, known as the Trans-Catheter Aortic Valve Replacement or TAVR, has shown stability in the reluctancy of hospitals to accept heart surgery